tirzepatide for the treatment of obstructive sleep apnea and obesity Breakthrough Treatment for Obstructive Sleep

Newer injectable peptides sold through the "grey market" FDA approval for peptides, such as insulin and GLP1s, ensures oversight of how these medications are manufactured and distributed

You should stick to a low-calorie diet and make healthy food choices

What Realistic Progress Looks Like Weight loss rarely follows a straight line

The SURMOUNT-1 Phase 3 trial published in the New England Journal of Medicine demonstrated 20.9% mean body weight reduction at 72 weeks on tirzepatide 15mg weekly versus 3.1% with placebo

Unlike Wegovy, Saxenda is administered daily, rather than weekly , and in research, Saxenda patients experienced an average loss of 5% of their body weight compared to Wegovy patients average weight loss of 15%